Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

831
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
831
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.6K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same author

COLLECTiEF dataset: A high-resolution indoor environmental dataset from European buildings across diverse climates supporting thermal, air-quality, and visual-comfort assessments.

Data in brief·2026
Same author

Centrally Acting Skeletal Muscle Relaxants Sharing Molecular Targets with Drugs for Neuropathic Pain Management.

Brain sciences·2026
Same author

The lifespan continuum of brain disorders: investigating links between neurodevelopmental and neurodegenerative disease-chicken or egg?

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Crosstalk Between Glycinergic and N-Methyl-D-Aspartate Receptor-Mediated Glutamatergic Transmission in Behaviours Associated with Opioid Use Disorder.

International journal of molecular sciences·2025
Same author

Resveratrol Analogs Ameliorate Mitochondrial Impairment and Insulin Resistance in a Streptozotocin-Induced In Vitro Model of Alzheimer's Disease.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jan 18, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.9K

Selegiline: a molecule with innovative potential.

Tamás Tábi1, László Vécsei2, Moussa B Youdim3

  • 1Department of Pharmacodynamics, Semmelweis University, Nagyvárad tér 4, 1089, Budapest, Hungary. tabi.tamas@pharma.semmelweis-univ.hu.

Journal of Neural Transmission (Vienna, Austria : 1996)
|September 29, 2019
PubMed
Summary

Monoamine oxidase B (MAO-B) inhibitors, like selegiline, are vital for Parkinson's disease treatment. Research highlights their potential for neuroprotection and disease modification, offering new therapeutic avenues.

Keywords:
DopamineMonoamine oxidase type B inhibitorsNeuroprotectionParkinson’s diseaseSelegiline

More Related Videos

Formulating and Characterizing an Exosome-based Dopamine Carrier System
06:08

Formulating and Characterizing an Exosome-based Dopamine Carrier System

Published on: April 4, 2022

3.6K
Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids
07:42

Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids

Published on: March 1, 2024

1.3K

Related Experiment Videos

Last Updated: Jan 18, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.9K
Formulating and Characterizing an Exosome-based Dopamine Carrier System
06:08

Formulating and Characterizing an Exosome-based Dopamine Carrier System

Published on: April 4, 2022

3.6K
Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids
07:42

Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids

Published on: March 1, 2024

1.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Monoamine oxidase B (MAO-B) inhibitors are established treatments for Parkinson's disease (PD), used alone or with levodopa.
  • Early research focused on MAO inhibitors for depression, but their potential in PD was recognized by Birkmayer, who observed benefits with levodopa.
  • Non-selective MAO inhibitors caused severe side effects, limiting their use, while MAO-B's role in brain dopamine metabolism was later clarified.

Purpose of the Study:

  • To review the historical development and evolving understanding of MAO-B inhibitors in Parkinson's disease therapy.
  • To highlight the key scientific contributions leading to the clinical application of selective MAO-B inhibitors.
  • To explore recent findings on the neuroprotective and disease-modifying potential of MAO-B inhibitors.

Main Methods:

  • Literature review of historical and recent studies on MAO-B inhibitors.
  • Analysis of pharmacological properties and clinical observations.
  • Examination of cell and molecular studies investigating mechanisms of action.

Main Results:

  • Selegiline was identified as a selective MAO-B inhibitor, crucial for its therapeutic application in PD.
  • MAO-B inhibitors, particularly when combined with levodopa, demonstrated efficacy in managing parkinsonian symptoms like akinesia.
  • Recent research indicates MAO-B inhibitors possess neuroprotective properties and may modify disease progression.

Conclusions:

  • MAO-B inhibitors have a significant and evolving role in managing Parkinson's disease.
  • The selective inhibition of MAO-B has overcome the limitations of earlier non-selective agents.
  • Emerging evidence suggests MAO-B inhibitors may offer disease-modifying benefits beyond symptomatic relief in PD.